New clinical trial results show mirikizumab helped over half of treatment-resistant Crohn’s patients achieve remission, with participants reporting improved quality of life and restored energy. This experimental drug represents promising progress in targeted IBD therapy.

New research suggests healthy plant-based diets rich in whole foods may help protect against IBD development. However, the quality of plant foods matters more than simply avoiding animal products, with processed plant foods offering no protective benefits.

Recent research shows the IBD and IBS treatment market is experiencing significant growth, driven by better diagnostics, increased awareness, and substantial investment in new therapies. This expansion could mean more personalized treatment options and improved quality of life for people living with inflammatory bowel disease.

AbbVie’s new pediatric Crohn’s study shows promising results for children with moderate to severe disease who haven’t responded to other treatments. The research offers hope for fewer symptoms and better remission maintenance in young patients.